Summary
The complement system represents an important nonspecific skin defense mechanism. Its activation leads to the generation of products that not only help to maintain normal host defenses but also mediate inflammation and tissue injury. Proinflammatory products of complement include large fragments of C3 with opsonic and cell-stimulatory activities (C3b and C3bi), low molecular weight anaphylatoxins (C3a, C4a, and C5a), and membrane attack complex. Among them C5a or its degradation product C5a des Arg seems to be the most important mediator because it exerts a potent chemotactic effect on inflammatory cells. Intradermal administration of C5a anaphylatoxin induces skin changes quite similar to those observed in cutaneous hypersensititivy vasculitis that occurs through immune complex-mediated complement activation. Complement activation is involved in the pathogenesis of the inflammatory changes in autoimmune bullous dermatoses. In pemphigus complement activation by pemphigus antibody in the epidermis seems to be responsible for the development of characteristic inflammatory changes termed eosinophilic spongiosis. In bullous pemphigoid (BP) interaction of basement membrane zone antigen and BP antibody leads to complement activation that seems to be related to leukocytes lining the dermoepidermal junction. Resultant anaphylatoxins not only activate the infiltrating leukocytes but also induce mast cell degranulation which facilitates dermoepidermal separation and eosinophil infiltration. Similar complement activation seems to play a more direct role in the dermoepidermal separation noted in epidermolysis bullosa acquisita and herpes gestationis. Anaphylatoxin generation via the alternative pathway activation under ligth irradiation is implicated in the development of the immediate erythematous phototoxic reactions induced by such well-known chemicals as porphyrin, chlorthiazide, demethylchlortetracycline, and chlorpromazine. It is known that a direct exposure of the stratum corneum to living skin tissues induces intense infammatory changes. In vitro study demonstrated that the stratum corneum activates complement via the antibody-independent alternative pathway to generate C5a anaphylatoxin. Thus, accumulated horny material from the follicular wall seems to play a crucial role in the induction of pustules in inflammatory acne lesions and abscesses in ruptured epidermal cysts via the activation of the alternative complement pathway. Meanwhile, in search for the chemotactic factors responsible for the transepidermal leukocyte chemotaxis noted in psoriasis and related sterile pustular dermatoses, we have detected the presence of unique chemotactic peptides in the scale extracts of lesional skin. Later studies identified the presence of C5a des Arg and IL-8 in this peptide fraction. The alternative complement pathway has been speculted for the complement activation at the subcorneal portion of the psoriatic epidermis by further immunological studies. Similar properties to activate the alternative complement pathway have been noted in various pathogenic fungi that induce inflammatory skin lesions. Generation of C5a anaphylatoxin beneath the fungus-laden stratum corneum seems to be responsible for the characteristic subcorneal pustule formation in superficial infections such as cutaneous candidiasis and dermatophytosis, whereas that around fungal spores in the dermis is presumed to play a role in the induction of mixed cell granuloma characterized by a dense neutrophil infiltration as noted in sporotrichosis and chromomycosis. AlthoughPityrosporum ovale constitutes ordinary skin microflora in seborrheic areas, its properties which activate complement via the alternative pathway are implicated in the pathogenesis of dandruff and seborrheic dermatitis, in which transepidermal neutrophil chemotaxis as noted in psoriasis is observed histopathologically.
Similar content being viewed by others
References
Belew PW, Rosenberg EW, Jennings BR (1980) Activation of the alternative pathway of complement byMalassezia ovalis (Pityrosporum ovale). Mycopathologia 70: 187–190
Beutner EH, Jarzabek-Chorzelska M, Jablonska S, Chorzelski TP, Rzesa G (1978) Autoimmunity in psoriasis. A complement immunofluorescence study. Arch Dermatol Res 261: 123–134
Briggaman RA, Schechter NM, Fraki J. Lazarus GS (1984) Degradation of the epidermal-dermal junction by proteolytic enzymes from human skin and human polymorphonucler leukocytes. J Exp Med 160: 1027–1042
Dahl MGC, McGjibbon DH (179) Complement C3 an dimmunoglobulin in inflammtory acne vulgaris. Br J Dermatol 101: 633–640
Dahl MV, Lindroos WE, Nelson RD (1978) Chemokinetic and chemotactic factors in psoriasis scale extracts. J Invest Dermatol 71: 402–406
Dalback K, Lofberg H, Dalback B (1986) Localization of vitronectin (S-protein of complement) in normal human skin. Acta Derm Venerol (Stockh) 66: 461–467
Dalziel K, Dykes PJ, Marks R (1984) Inflammation due to intracutaneous implantation of stratum corneum. Br J Exp Pathol 65: 107–125
Emmerson RW, Wilson Jones E (1968) Eosinophilic spongiosis in pemphigus. Arch Dermatol 97: 252–267
Fincham NJ, Camp RDR, Gearing AJH, Bird CR, Cunningham FM (1988) Neutrophil chemoattractant and IL-1-like activity in samples from psoriatic lesions: further characterization. J Immunol 140: 4249–4299
Gammon WR, Lewis DM, Carlo JR, Sams WM Jr. Wheeler CE (1980) Pemphigoid antibody mediated attachment of peripheral blood leukocytes at the dermal-epidermal junction of human skin. J Invest Dermatol 75: 334–339
Gammon WR, Inman AO III, Wheeler CE Jr (1984) Differences in complement-dependent chemotactic acitivity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes, demonstration by leukocyte attachment and organ culture methods. J Invest Dermatol 83: 57–61
Gigli I (1981) The complement system. Mechanisms of action, biology, and participation in dermatological diseases. In: Safai B, Good RA (eds) Immunodermatology. Plenum, New York, pp 65–100
Goldstein IM (1988) Complement: biologically active products In: Gallin JI, Goldstein IM, Snyderman R (ed) Inflammation. Basic principles and clinical correlates. Raven, New York, pp 55–74
Hashimoto T, Sugiura M, Kurihara S, Nishikawa T (1982) In vitro complement activation by intercellular antibodies. J Invest Dermatol 78: 316–318
Hashimoto K, Jensen PJ, Lazarus GS (1989) In vitro studies of acantholysis of keratinocytes induced by pemphigus antibody. In: Norris DA (eds) Immune mechanisms in cutaneous disease. Marcel Dekker, New York, pp 277–290
Iwatsuki K, Tagami H, Yamada M (1983) Induction of leukocyte adherence at the basement membrane zone with subsequent activation of their metabolic pathway by pemphigoid antibodies and complement. Acta Derm Venereol (Stockh) 63: 290–295
Iwatsuki K, Tagami H, Yamada M (1983) Pemphigus antibodies mediate the development of inflammatory change in the epidermis. Acta Derm Venereol (Stockh) 63: 495–500
Jungi T, McGregor DD (1979) Role of complement in the expression of delayed-type hypersensitivity in rats: studies with cobra venom factor. Infect Immun 23: 633–643
[Reference deleted]
Kaneko J, Gushiken H, Kawagishi M, Miura Y, Kobayashi K, Konno T (1980) Analysis of immunological responses in psoriatic lesions. I. Immunopathological studies on psoriatic lesions. J Invest Dermatol 1980; 75: 436–439
Kato T, Terui T, Takematsu H, Tagami H (1989) Effects of psoriatic scale extracts on oxidative metabolic responses in granulocytes assessed by chemiluminescence. Inflammation 13: 59–66
Katz SI, Hertz KC, Yaoita H (1976) Herpes gestationis: immunopathology and characterization of the HG factor. J Clin Invest 57: 1434–1441
Kawana S, Geoghegan WD, Jordon RE (1985) Complement fixation by pemphigus antibody. II. Complement enhanced detachment of epidermal cells. Clin Exp Immunol 61: 517–525
Kikuchi, T, Horii I, Sakamoto T, Nakayama Y, Tagami H (1989) Demonstration of neutrophil chemotactic anaphylatoxins in human dandruff. Arch Dermatol Res 281: 482–486
Krogh HK (1969) Antibodies in human sera to stratum corneum. Int Arch Allergy 36: 415–426
Leeming JP, Ingham E, Cunliffe WJ (1988) The microbial content and complement C3 cleaving capacity of comedones in acne vulgaris. Acta Derm Venereol (Stockh) 68: 468–473
Lim HW, Gigli J (1981) The role of complement in phototoxic reactions. Springer Semin Immunopathol 4: 209–219
Lim HW, Perez HD, Poh-Fizpatrick M, Goldstein IM, Gigli I (1981) Generation of chemotactic activity in serum from patients with erythorpoietic protoporphyria and porphyria cutanea tarda. N Engl J Med 304: 212–216
Lim HW, Novotny H, Gigli I (1983) Role of complement and polymorphonuclear cells in demethylchlortetracycline-induced phototoxicity in guinea pigs inhibited by decomplementation in vivo. J Clin Invest 71: 1326–335
Lim HW, He D, Esquenazi-Behar S, Yancey KB, Soter NA (1991). C5a cutaneous mast cells and inflammation in vitro and in vitro studies in murine models. J Invest Dermatol 97: 305–311
Maibach HI, Kligman AM (1962) The biology of experimental human cutaneous moniliasis. Arch Dermatol 85: 233–257
Marley WM, Belew PW, Rosenberg EW, Urmson JR, Stizel E, Spitzer RE (1982) Abnormalities in the alternative pathway of complement in psoriasis. Clin Exp Dermatol 7: 387–396
Müller-Eberhardt HJ (1984) The membrane attack complex. Springer Semin Immunopathol 7: 93–141
Naito K, Morioka S, Ikeda S, Ogawa H (1984) Experimental bullous pemphigoid in guinea pigs: the role of pemphigoid antibodies complement, and migrating cells. J Invest Dermatol 82: 227–230
Norris JFB, Cunliffe WJ (1988) A histological and immunocytochemical study of early acne lesions. Br J Dermatol 118: 651–659
Ohkhochi K, Takematsu H, Tagami H (1985) Increased anaphylatoxins (C3a and C4a) in psoriatic sera. Br J Dermatol 113: 189–196
Ohkhochi K, Takematsu H, Tagami H (1986) Determination of anaphylatoxin concentrations in suction blisters in patients with psoriasis. J Invest Dermatol 87: 65–67
Ohkhochi K, Torinuki W, Tagami H (1989) Plasma concentrations of complement-modulating proteins (C1 inhibitor, C4 binding protein, factor H and factor I) in inflammatory dermatoses with special reference to psoriasis. Dermatologica 179: 30s-34s
Pinkus H, Mehregan AH (1966) The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Dermatol 46: 109–116
Rauterberg A, Jung EG, Burger R, Rauterberg EW (1990) Phototoxic erythema following PUVA treatment: independence of complement. J Invest Dermatol 94: 144–149
Ray TL, Wuepper KD (1976) Activation of the alternative (properdin) pathway of complement byCandida albicans and related species. J Invest Dermatol 67: 700–703
Ray TL, Wuepper KD (1978) Experimental cutaneous candidiasis in rodents. II. Role of the stratum corneum barrier and serum complement as a mediator of a protective inflammatory response. Arch Dermatol 114: 539–543
Rosenberg EW, Noah PW, Wyatt RJ, Jones RM, Kolb WP (1990) Complement activation in psoriasis. Clin Exp Dermatol 15: 16–20
Sayama K, Shiraishi S, Shirakata Y, Kobayashi Y, Miki Y (1991) Characterization of decay-accelerating factor (DAF) in human skin. J Invest Dermatol 96: 61–64
Schröder J-M (1992) Generation of NAP-1 and related peptides in psoriatic and other inflammatory skin diseases. In: Baggiolini M, Sorg C (eds) Interleukin-8 (NAP-1) and related chemotactic cytokines, vol. 4. Cytokines, Karger, Basel, pp 54–76
Schröder J-M, Christophers E (1985) Transient absence of C5a-specific neutrophil function in inflammatory disorders of the skin. J Invest Dermatol 85: 194–198
Scott D, Cunliffe W, Gowland G (1979) Activation of complement — a mechanism for the inflammation in acne. Br J Dermatol 101: 315–320
Shuster S (1984) The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 111: 235–242
Sohnle PG, Hahn BL (1989) Epidermal proliferation and the neutrophilic infiltrates of experimantal cutaneous candidiasis in mice. Arch Dermatol Res 281: 279–283
Swan JW, Dahl MV, Coppo PA, Hammerschmidt DE (1983) Complement activation byTrichophyton rubrum. J Invest Dermatol 80: 156–158
Swerlick RA, Yancey KB, Lawley T (1988) A direct in vivo comparison of the inflammatory properties of human C5a and C5a des Arg in human skin. J Immunol 140: 2376–2381
Tagami H (1985) Epidermal cell proliferationin guinea pigs with experimental dermatophytosis. J Invest Dermatol 85: 153–155
Tagami H, Imamura S, Noguchi S, Nishitani H (1976) Coexistence of peculiar pemphigus, myasthenia gravis and malignant thymoma. Dermatologica 152: 181–190
Tagami H, Ofuji S (1976) Leukotactic properties of soluble substances in psoriasis scale. Br J Dermatol 95: 1–8
Tagami H, Ofuji S (1977) Characterization of a leukotactic factor derived from psoratic scale. Br J Dermatol 97: 509–511
Tagami H, Watanabe S, Ofuji S, Minami K (1977) Trichophytin contact sensitivity in patients with dermatophytosis. Arch Dermatol 113: 1409–1414
Tagami H, Ofuji S (1978) A leukotactic factor in the stratum corneum of pustulosis palmaris et plantaris: a possible mechanism for the formation of intra-epidermal strerile pustules. Acta Derm Venereol (Stockh) 58: 401–405
Tagami H, Natsume N, Aoshima T, Yamada M (1982) Analysis of transepidermal leukocyte chemotaxis in experimental dermatophytosis in guinea pigs. Arch Dermatol Res 273: 205–217
Tagami H, Iwatsuki K, Iwase Y, Yamada M (1983) Subcorneal pustular dermatosis with vesiculo-bullous eruption Demonstration of IgA deposis at the intercellular portion of the upper epidermis and a leukocyte chemotactic factor. Br J Dermatol 109: 581–587
Tagami H, Iwatsuki K, Yamada M (1983) Profile of antistratum corneum autoantibodies in psoriatic patients. Arch Dermatol Res 275: 71–75
Tagami H, Urano-Suehisa S, Hatchome N (1985) Contact sensitivity toCandida albicans — comparative studies in man and animal (guinea pig). Br J Dermatol 113: 415–424
Takematsu H, Tagami H (1990) Activation of the alternative pathway of complement in psoriatic lesional skin. Dermatologica 181: 298–292
Takematsu H, Tagami H (1992) Preferential activation of the alternative pathway of complement in psoriatic lesional skin. Dermatology 184: 159–160
Takematsu H, Ohkohchi K, Tagami H (1986) Demonstration of anaphylatoxins (C3a, C4a and C5a) in the scale of psoriasis and inflammatory pustular dermatoses. Br J Dermatol 114: 1–6
Takematsu H, Terui T, Tagami H (1986) Demostration of leukotriene B4 in scale extracts of psoriasis and inflammatory pustular dermatoses. Correlation with leukocyte chemotactic activity and C5a anaphylatoxin. Acta Derm Venereol (Stockh) 66: 6–10
Takematsu H, Terui T, Ohkohchi K, Tagami H, Suzuki R, Kumagai K (1986) Presence of chemotactic peptides other than C5a anaphylatoxin in scales of psoriasis and sterile pustular dermatoses. Acta Derm Venereol (Stockh) 66: 93–97
Takematsu H, Terui T, Torinuki W, Tagami H (1987) Leukocyte chemotactic properties of soluble horny contents in epidermal cysts. Arch Dermatol Res 279: 449–453
Takematsu H, Isono N, Kato T, Tagami H (1990) Normal human epidermal keratinocyte-derived neutrophil chemotactic factor. Tohoku J Exp Med 162: 1–13
Terui T, Aiba S, Kato T, Tanaka T, Tagami H (1987) HLA-DR antigen expression on keratinocyte in highly inflamed parts of psoriatic lesions. Br J Dermatol 116: 87–93
Terui T, Rokugo M, Kato T, Tagami H (1989) Analysis of the pro-inflammatory property of epidermal cyst contents: chemotactic C5a anaphylatoxin generation. Arch Dermatol Res 281: 31–34
Terui T, Kato T, Tagami H (1989) Stratum corneum activation of complement through the antibody-independent alternative pathway. J Invest Dermatol 92: 593–597
Torinuki W, Tagami H (1985) Complement activation bySporotrix schenckii. Arch Dermatol Res 277: 332–333
Torinuki W, Tagami H (1986) The role of chlorpromazine-induced phototoxicity. J Invest Dermatol 86: 142–144
Torinuki W, Miura T, Tagami H (1984) Activation of the alternative complement pathway by 405 nm light in serum from porphyric rat. Acta Derm Venereol (Stockh) 64: 367–372
Torinuki W, Ohkohchi K, Takematsu H, Tagami H (1984) Activation of the alternative complement pathway byFonsecaea pedrosoi. J Invest Dermatol 83. 308–310
Webster G, Leyden J, Nilsson U (1979) Complement activation in acne vulgaris: consumption of complement by comedones. Infect Immun 26: 183–186
Werth VP, Ivanov IE, Nussenzweig V (1988) Decay-accelerating factor is associated with elastic fibers. J Invest Dermatol 91: 511–516
Yancey KB, Hammer CH, Harvath L, Renfer L, Frank MM, Lawley TJ (1985) Studies of human C5a as a mediator of inflammation in normal human skin. J Clin Invest 75: 486–495
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tagami, H. The role of complement-derived mediators in inflammatory skin diseases. Arch Dermatol Res 284 (Suppl 1), S2–S9 (1992). https://doi.org/10.1007/BF00638232
Issue Date:
DOI: https://doi.org/10.1007/BF00638232